The Brand Name DIBIGLIM Has Generic Salt :: Glimepiride 

DIBIGLIM  Is From Company NOVARTIS(SANDOZ) Priced :: Rs. 250.00/400.00

DIBIGLIM have Glimepiride is comes under Sub class Insulin , Anti Diabetic drugs of  Main Class Endocrine,Steroid Hormones , Metabolic System

Main Medicine Class:: Endocrine,Steroid Hormones , Metabolic System  Sub Medicine Class :: Insulin , Anti Diabetic drugs 

Indications for Drugs ::

Type 2 DM

Drug Dose ::

Oral Type 2 diabetes mellitus Adult: Initially, 1-2 mg daily. May be increased in increments of 1-2 mg at intervals of 1-2 wk. Maintenance: 4 mg daily. Max: 6 mg daily. Elderly: Initially, 1 mg once daily. Hepatic impairment: Severe: Contraindicated.

Contraindication ::

Diabetic ketoacidosis with or without coma.

Drug Precautions ::

Increased risk of CV mortality. Elderly; hepatic and renal impairment. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in patients with CHF or hepatic cirrhosis. Monitor blood-glucose concentration. Pregnancy, lactation.

Drug Side Effects ::

Vomiting, GI pain, diarrhoea; pruritus, erythema, urticaria, morbilliform, maculopapular eruptions; leukopenia, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia and pancytopenia; hyponatraemia; changes in accommodation, blurred vision, jaundice.

Pregnancy category ::

3

Drug Mode of Action ::  

Glimepiride stimulates the insulin release from pancreatic ?-cells and reduces glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.

Drug Interactions ::

Salicylates, sulfonamides, chloramphenicol, clarithromycin, coumarin anticoagulants, probenecid, CYP2C9 inhibitors, fibric acid derivatives, disopyramide, fluoxetine, quinolones, ACE inhibitors, MAOIs and ?-blockers may potentiate the hypoglycaemic action of glimepiride. Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, phenytoin, nicotinic acid, sympathomimetics and CYP2C9 inducers may reduce hypoglycaemic effect of glimepiride. Reduced plasma concentration w/ colesevelam.